Medicare Enrolled
Dr. David Dspain, D.O.
Internal Medicine · Granbury, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Dspain from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Dspain? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Dspain
Dr. David Dspain is an internal medicine in Granbury, TX, with 18 years in practice. Based on federal Medicare data, Dr. Dspain performed 210,587 Medicare services across 4,821 unique beneficiaries.
Between the years covered by Open Payments, Dr. Dspain received a total of $1,878 from 37 pharmaceutical and/or device companies across 96 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Dspain is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice▲ Top 0% volume in TX$ $1,878 industry payments
Medicare Practice Summary
Medicare Utilization ↗210,587
Medicare services
Top 0% in TX for internal medicine
4,821
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~11,699 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 42,840 | $0 | $5 |
| Oxaliplatin chemotherapy injection | 31,980 | $0 | $33 |
| Anti-nausea injection (fosaprepitant) | 29,400 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 22,000 | $42 | $136 |
| Paclitaxel chemotherapy injection | 12,706 | $0 | $8 |
| Darbepoetin injection (Aranesp) for anemia | 9,000 | $2 | $20 |
| Immune globulin infusion (Octagam) | 8,808 | $34 | $234 |
| Injection, durvalumab, 10 mg | 8,060 | $62 | $197 |
| Denosumab injection (Prolia/Xgeva) | 7,140 | $18 | $66 |
| Dexamethasone injection (steroid) | 5,665 | $0 | $1 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 3,210 | $22 | $181 |
| Epoetin alfa injection (Procrit) for anemia | 3,195 | $6 | $51 |
| Epoetin alfa injection (Retacrit) for anemia | 3,160 | $6 | $28 |
| Anti-nausea injection (Aloxi/palonosetron) | 2,800 | $1 | $114 |
| Injection, leucovorin calcium, per 50 mg | 2,395 | $3 | $25 |
| Injection, granisetron hydrochloride, 100 mcg | 1,590 | $0 | $24 |
| Injection, fluorouracil, 500 mg | 1,400 | $2 | $13 |
| Blood draw (venipuncture) | 1,282 | $8 | $20 |
| Complete blood count (CBC) with differential | 1,160 | $8 | $36 |
| Infliximab infusion (Remicade) | 1,130 | $19 | $294 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 979 | $22 | $157 |
| Administration of chemotherapy into vein, 1 hour or less | 819 | $96 | $707 |
| Office visit, established patient (30-39 min) | 748 | $93 | $368 |
| Comprehensive metabolic blood panel | 745 | $10 | $64 |
| Drug injection, under skin or into muscle | 508 | $10 | $96 |
| Injection, carboplatin, 50 mg | 487 | $2 | $300 |
| Injection, zoledronic acid, 1 mg | 452 | $7 | $431 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 441 | $47 | $313 |
| Lactate dehydrogenase (enzyme) level | 408 | $6 | $31 |
| Flow cytometry, additional marker | 391 | $19 | $180 |
| Magnesium level test | 385 | $7 | $29 |
| Administration of chemotherapy into vein, each additional hour | 346 | $21 | $161 |
| Injection, diphenhydramine hcl, up to 50 mg | 301 | $1 | $7 |
| Administration of additional new drug or substance into vein, 1 hour or less | 290 | $47 | $344 |
| Injection of additional new drug or substance into vein | 221 | $12 | $108 |
| Injection, magnesium sulfate, per 500 mg | 200 | $1 | $6 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 197 | $133 | $3,675 |
| Infusion, normal saline solution , 1000 cc | 183 | $2 | $19 |
| Injection, iron dextran, 50 mg | 178 | $13 | $43 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 170 | $15 | $100 |
| Ferritin level test (iron stores) | 163 | $13 | $60 |
| Iron level test | 163 | $6 | $27 |
| Iron binding capacity test | 163 | $8 | $35 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 159 | $54 | $211 |
| Immunoglobulin level test | 147 | $9 | $56 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 147 | $123 | $500 |
| Microscopic examination for white blood cells with manual cell count | 146 | $4 | $22 |
| Complete blood count (CBC), automated | 146 | $6 | $34 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 141 | $272 | $2,762 |
| New patient office visit (45-59 min) | 137 | $117 | $565 |
| Unclassified drugs | 136 | $1 | $8 |
| Office visit, established patient (20-29 min) | 126 | $64 | $250 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 117 | $89 | $657 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 115 | $1 | $19 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 112 | $1,093 | $4,802 |
| Vitamin B-12 level test | 102 | $15 | $76 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 101 | $15 | $94 |
| Infusion into a vein for hydration, 31-60 minutes | 96 | $24 | $256 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 84 | $24 | $145 |
| Measurement of immunoglobulin light chains | 80 | $17 | $60 |
| Infusion into a vein for hydration, each additional hour | 74 | $10 | $75 |
| Urinalysis, manual | 61 | $3 | $15 |
| Irrigation of implanted venous access drug delivery device | 57 | $19 | $114 |
| Drawing of blood for a medical problem | 51 | $61 | $264 |
| PSA test (prostate cancer screening) | 48 | $18 | $94 |
| Carcinoembryonic antigen (cea) protein level | 47 | $19 | $99 |
| Administration of additional new drug or substance into vein using push technique | 43 | $42 | $289 |
| Beta-2 microglobulin (protein) level | 39 | $16 | $96 |
| Basic metabolic blood panel | 35 | $8 | $49 |
| New patient office visit (30-44 min) | 35 | $77 | $372 |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 30 | $4 | $33 |
| Red blood count automated, with additional calculations | 24 | $5 | $26 |
| Office visit, established patient, complex (40-54 min) | 21 | $126 | $496 |
| Nuclear medicine study whole body with ct scan | 19 | $1,103 | $4,929 |
| Folic acid level test | 18 | $14 | $73 |
| Stool analysis for blood to screen for colon tumors | 17 | $4 | $24 |
| Flow cytometry technique for dna or cell analysis, first marker | 17 | $59 | $298 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
26.2% high complexity
70.1% medium
3.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$1,878
Total received (2018-2024)
Avg $313/year across 6 years
Top 30% in TX for internal medicine
37
Companies
96
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,449 (77.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$429 (22.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$641
2023$238
2022$82
2021$25
2019$546
2018$346
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$228
Janssen Biotech, Inc.
$215
Novartis Pharmaceuticals Corporation
$139
Sirtex Medical Inc
$112
Janssen Products, LP
$77
Incyte Corporation
$76
SERVIER PHARMACEUTICALS LLC
$75
Genentech USA, Inc.
$74
Stryker Corporation
$70
E.R. Squibb & Sons, L.L.C.
$63
ARRAY BIOPHARMA INC
$62
Puma Biotechnology, Inc.
$60
GlaxoSmithKline, LLC.
$53
AstraZeneca Pharmaceuticals LP
$53
Tempus AI, Inc
$52
Eisai Inc.
$48
GENZYME CORPORATION
$37
Astellas Pharma US Inc
$35
EMD Serono, Inc.
$33
SOBI, INC
$26
Mirati Therapeutics, Inc.
$24
Regeneron Healthcare Solutions, Inc.
$24
Sun Pharmaceutical Industries Inc.
$21
Bayer Healthcare Pharmaceuticals Inc.
$20
Amgen Inc.
$19
Ipsen Biopharmaceuticals, Inc
$19
Takeda Pharmaceuticals U.S.A., Inc.
$17
SANOFI-AVENTIS U.S. LLC
$17
EISAI INC.
$17
Medtronic, Inc.
$17
Bayer HealthCare Pharmaceuticals Inc.
$16
BeiGene USA, Inc.
$16
ABBVIE INC.
$15
Seagen Inc.
$13
Acrotech Biopharma LLC
$12
Gilead Sciences, Inc.
$12
Seattle Genetics, Inc.
$11
Top 3 companies account for 31.0% of total payments
Associated products mentioned in payments ›
ADCETRIS · Alecensa · Avastin · BAVENCIO · BELEODAQ · BOSULIF · Bavencio · CABLIVI · CALQUENCE · DARZALEX · DAURISMO · DOPTELET · ELAHERE · Erleada · IBRANCE · IMBRUVICA · INLYTA · JAKAFI · JEVTANA · KISQALI · KRAZATI · LIBTAYO · LYNPARZA · Lenvima · MEKINIST · MONJUVI · NERLYNX · Nerlynx · Nplate · Nubeqa · OJJAARA · OPDIVO · OPTABLATE · OSTEOCOOL RF ABLATION SYSTEM · PROMACTA · RYBREVANT · SARCLISA · SIR-Spheres Microspheres · SOMATULINE DEPOT · SUTENT · TALZENNA · TASIGNA · TECENTRIQ · TEVIMBRA · Tibsovo · VENCLEXTA · Vitrakvi · XALKORI · XTANDI · Xtandi · YONSA · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (77%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $1 per 100 Medicare services performed
Geographic Context
Internal Medicines within 10 mi
47
Per 100K population
73.2
County median income
$86,802
Nearest hospital
LAKE GRANBURY MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Dspain is a mixed practice specialist, with above-average Medicare volume (top 0% in TX), and low-engagement industry engagement, with 18 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Dspain experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Dspain performed 42,840 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Dspain receive payments from pharmaceutical companies?
Yes. Dr. Dspain received a total of $1,878 from 37 companies across 96 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Dspain's costs compare to other internal medicines in Granbury?
Dr. Dspain's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Dspain) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicines in Granbury
Browse internal medicines in Granbury ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicines in TX
Internal Medicines ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicines in TX
Which TX internal medicines receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology